Revlimid and Keratitis - a phase IV clinical study of FDA data

Summary:

Keratitis is reported as a side effect among people who take Revlimid (lenalidomide), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Dexamethasone, and have Acute myeloid leukaemia.

The phase IV clinical study analyzes which people have Keratitis when taking Revlimid. It is created by eHealthMe based on reports of 377,717 people who have side effects when taking Revlimid from the FDA, and is updated regularly.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

What is Keratitis?

Keratitis (eye's cornea, the front part of the eye, becomes inflamed) is found to be associated with 414 drugs and 838 conditions by eHealthMe. Check the latest studies of Keratitis.

On Jul, 26, 2026

377,717 people reported to have side effects when taking Revlimid.
Among them, 29 people (0.01%) have Keratitis.

Among these 29 people:

How long have people been on Revlimid when they have Keratitis? *

What is the gender of people who have Keratitis when taking Revlimid? *

female: 35 %
male: 65 %

What is the age of people who have Keratitis when taking Revlimid? *

What are other drugs people take besides Revlimid? *

What are other side effects people have besides Keratitis? *

Visual Acuity Reduced (reduced clearness of vision): 9 people, 31.03%
Neuropathy Peripheral (surface nerve damage): 7 people, 24.14%
Cataract (clouding of the lens inside the eye): 7 people, 24.14%
Death: 7 people, 24.14%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 5 people, 17.24%
Abdominal Pain: 5 people, 17.24%
Weakness: 5 people, 17.24%
Anaemia (lack of blood): 5 people, 17.24%
Rashes (redness): 4 people, 13.79%
Pneumonia: 4 people, 13.79%

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 6.90%
Amyloidosis (a tumour within which amyloid is produced): 2 people, 6.90%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 6.90%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 6.90%
Thrombocytopenia (decrease of platelets in blood): 1 person, 3.45%
Rashes (redness): 1 person, 3.45%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 3.45%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 3.45%
Insomnia (sleeplessness): 1 person, 3.45%
High Density Lipoprotein Decreased: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and have Keratitis?

- Check whether Keratitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Revlimid:

Revlimid (378,026 reports)

Keratitis treatments and more:

Keratitis (4,120 reports)

Browse all side effects of Revlimid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Keratitis:

Keratitis (414 drugs)

Browse all the conditions that are associated with Keratitis:

Keratitis (838 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.